Repligen corp stock.

Repligen Corp. (RGEN) current stock price is $159.46 with a 24-hour trading volume of 392.47K. The stock decreased by -1.43% in the last 24 hours and rose by +33.35% in the past month. Looking at the chart, RGEN stock price is below the pivot point level of $161.1, suggesting a potential bearish market, if it continues to fall close to the support level of …On November 14, 2023, Repligen Corporation (NASDAQ:RGEN) stock closed at $153.79 per share. One-month return of Repligen Corporation (NASDAQ:RGEN) was 7.92%, and its shares lost 19.47% of their ...Repligen ( NASDAQ: RGEN) is owned by 101.54% institutional shareholders, 37.70% Repligen insiders, and 0.00% retail investors. Bvf Partners L P is the largest individual Repligen shareholder, owning 11.06M shares representing 19.81% of the company. Bvf Partners L P's Repligen shares are currently valued at $1.76B.Repligen Corp’s stock is NA in 2023, NA in the previous five trading days and down 14.71% in the past year. Currently, Repligen Corp’s price-earnings ratio is 47.0. Repligen Corp’s trailing 12-month revenue is $777.8 million with a 21.6% net profit margin. Year-over-year quarterly sales growth most recently was -11.5%.View the latest Repligen Corp. (RGEN) stock price, news, historical charts, analyst ratings and financial information from WSJ.

Repligen Announces Publication of the Company’s 2022 Sustainability Report November 14, 2023TipRanks. Repligen price target lowered to $150 from $165 at Deutsche Bank November 7, 2023TipRanks ...Repligen Corp stock has a Growth Score of 82, Momentum Score of 48 and Quality Score of 71. Comparing Baxter International Inc and Repligen Corp’s grades, scores and metrics can act as a solid basis to determine whether they may be a good investment or not. You’ll also want to look at your portfolio’s asset allocation as well as …Fundamentals REPLIGEN CORP. DL-,01. Dividend. Dividend yield in %. P/E Ratio. Profit per share. Number of shares. Market capitalization. News about REPLIGEN ...

Repligen's (RGEN) third-quarter earnings and revenues surpass estimates. The company tightens revenue guidance for 2023. Shares rise. Get the latest Repligen Corporation …Repligen Corp’s stock is NA in 2023, NA in the previous five trading days and down 15.77% in the past year. Currently, Repligen Corp’s price-earnings ratio is 65.8. Repligen Corp’s trailing 12-month revenue is $729.3 million with a 18.9% net profit margin. Year-over-year quarterly sales growth most recently was -23.3%.

On September 12, 2023, Repligen Corp (HONE) stock performed well, with a median target price forecast of $200.00. The consensus among the 13 polled investment analysts is to buy stock in Repligen Corp. Repligen Corp is expected to release its current quarter earnings report on October 26. The company is projected to have earnings per share of ...Repligen Corp stock has a Growth Score of 82, Estimate Revisions Score of 37 and Quality Score of 71. Comparing Bio Rad Laboratories Inc and Repligen Corp’s grades, scores and metrics can act as a solid basis to determine whether they may be a good investment or not. You’ll also want to look at your portfolio’s asset allocation as well …America’s largest Marine Corps bases include North Carolina’s Marine Corps Base Camp Lejeune, and California’s Marine Corps Air Ground Combat Center Twentynine Palms and Marine Corps Base Camp Pendleton.Repligen Corp’s stock is NA in 2023, NA in the previous five trading days and down 10.83% in the past year. Currently, Repligen Corp’s price-earnings ratio is 50.0. Repligen Corp’s trailing 12-month revenue is $801.5 million with a 23.2% net profit margin. Year-over-year quarterly sales growth most recently was 0.2%.

Apr 25, 2023 · Repligen Corp’s ( RGEN) price is currently down 11.17% so far this month. During the month of April, Repligen Corp’s stock price has reached a high of $182.42 and a low of $149.02. Over the last year, Repligen Corp has hit prices as high as $262.26 and as low as $137.21. Year to date, Repligen Corp’s stock is down 43.53%.

Repligen Corp’s stock is NA in 2023, NA in the previous five trading days and down 27.1% in the past year. Currently, Repligen Corp’s price-earnings ratio is 68.5. Repligen Corp’s trailing 12-month revenue is $729.3 million with a 18.9% net profit margin. Year-over-year quarterly sales growth most recently was -23.3%.

Oct 9, 2023 · With its stock down 4.8% over the past month, it is easy to disregard Repligen (NASDAQ:RGEN). However, stock prices are usually driven by a company’s financials over the long term, which in this ... The number of shares of the Company's common stock, $0.01 par value per share ("Common Stock"), entitled to vote at the Annual Meeting was 55,429,107. The number of shares of Common Stock present or represented by valid proxy at the Annual Meeting was 51,525,212, representing 92.96% of the total number of shares of Common …Reports first quarter revenue of $182.7 million, with base business growth of 4% as reported and 7% at constant currency Reports first quarter gross margin of 55.2% on both GAAP and adjusted (non-GAAP) basis Closed on acquisition of single-use bag manufacturer FlexBiosys Inc. in April WALTHAM, Mass., May 02, 2023 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN), a life sciences company ...Repligen Corp’s stock is NA in 2023, NA in the previous five trading days and down 22.3% in the past year. Currently, Repligen Corp’s price-earnings ratio is 64.0. Repligen Corp’s trailing 12-month revenue is $729.3 million with a 18.9% net profit margin. Year-over-year quarterly sales growth most recently was -23.3%.Repligen - RGEN - Stock Price Today - Zacks Repligen (RGEN) (Delayed Data from NSDQ) $164.94 USD +7.69 (4.89%) Updated Dec 1, 2023 04:00 PM ET After-Market: $161.40 -3.54 (-2.15%) 7:58 PM ET...

Nov 30, 2023 · The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. Repligen Corp. shares valued at $557,328 were sold by Gebski Christine on Nov 10. At $147.13 per share, Gebski Christine sold 3,788 shares. Complete Repligen Corp. stock information by Barron's. View real-time RGEN stock price and news, along with industry-best analysis.Repligen Corp (NASDAQ:RGEN) 157.02 Delayed Data As of Nov 21 +1.38 / +0.89% Today’s Change 110.45 Today ||| 52-Week Range 200.98 -7.26% Year-to-Date Quote …Find the latest Repligen Corporation (RGEN) stock quote, history, news and other vital information to help you with your stock trading and investing.Repligen Corp. (RGEN) current stock price is $159.46 with a 24-hour trading volume of 392.47K. The stock decreased by -1.43% in the last 24 hours and rose by +33.35% in the past month. Looking at the chart, RGEN stock price is below the pivot point level of $161.1, suggesting a potential bearish market, if it continues to fall close to the support level of …Find the latest Repligen Corp (RGN.MU) stock quote, history, news and other vital information to help you with your stock trading and investing.

Oct 18, 2023 · Repligen Corp’s stock is NA in 2023, NA in the previous five trading days and down 30.36% in the past year. Currently, Repligen Corp’s price-earnings ratio is 58.9. Repligen Corp’s trailing 12-month revenue is $729.3 million with a 18.9% net profit margin. Year-over-year quarterly sales growth most recently was -23.3%. Repligen Corp’s stock is NA in 2023, NA in the previous five trading days and down 22.25% in the past year. Currently, Repligen Corp’s price-earnings ratio is 66.4. Repligen Corp’s trailing 12-month revenue is $729.3 million with a 18.9% net profit margin. Year-over-year quarterly sales growth most recently was -23.3%.

Repligen does not undertake to update, ... 2022, the Company had the option to settle the conversion of the 2019 Notes in cash, stock or a combination of the two. Therefore, from January 1, 2022 ...Complete Repligen Corp. stock information by Barron's. View real-time RGEN stock price and news, along with industry-best analysis.Repligen Corp’s trailing 12-month revenue is $729.3 million with a 18.9% net profit margin. Year-over-year quarterly sales growth most recently was -23.3%. Analysts expect adjusted earnings to reach $1.752 per share for the current fiscal year. Repligen Corp does not currently pay a dividend. How We Compare Steris PLC and Repligen Corp Stock ...T&C apply*. Buy Repligen Corp Shares from India at $157.25 (0 Commission) today. Start investing in Repligen Corp stocks from India now with fractional investing only on INDmoneyapp.Sep 15, 2022 09:19AM EDT. Today we're going to take a look at the well-established Repligen Corporation (NASDAQ:RGEN). The company's stock saw a significant share price rise of over 20% in the ...Information on stock, financials, earnings, subsidiaries, investors, and executives for Repligen. Use the PitchBook Platform to explore the full profile. ... Repligen Corp is a global life sciences company. It develops and commercializes innovative bioprocessing technologies an. Biotechnology. Waltham, MA. 2,025 As of 2022 00000000. 000000.The share price of Repligen Corp. (NASDAQ:RGEN) dipped -2.38% to close Friday’s market session at $119.58, lower as compared to yesterday’s close. The stock price fluctuated between $118.08 and $122.45 throughout the trading session with the volume trading being 788849 shares, which represented a significant variation when …

7.05%. Trailing 12-Months. The Repligen Holdings stock analysis is based on the TipRanks Smart Score which is derived from 6 unique data sets including Analyst recommendations, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.

Repligen Corp stock has a Momentum Score of 57, Estimate Revisions Score of 50 and Quality Score of 73. Comparing DexCom, Inc. and Repligen Corp’s grades, scores and metrics can act as a solid basis to determine whether they may be a good investment or not. You’ll also want to look at your portfolio’s asset allocation as well as …

The current consensus among 14 polled investment analysts is to buy stock in Repligen Corp. This rating has held steady since August, indicating a consistent belief in the company’s potential for growth. Repligen Corp has reported strong financials for the current quarter, with earnings per share of $0.55 and sales of $179.5 million.Nov 24, 2023 · In 2022, Repligen's revenue was $801.54 million, an increase of 19.54% compared to the previous year's $670.53 million. Earnings were $185.96 million, an increase of 44.95%. Financial Statements. Repligen Corp., which was founded by Alexander G., provides bioprocessing technologies and services utilized in producing biological drugs. ... With institutions owning 91% of its stock, it’s clear that Repligen is attracting some serious attention from experienced and savvy investors who see its potential for growth in the biotech sector ...Oct 9, 2023 · With its stock down 4.8% over the past month, it is easy to disregard Repligen (NASDAQ:RGEN). However, stock prices are usually driven by a company’s financials over the long term, which in this ... Track Repligen Corp. (RGEN) Stock Price, Quote, latest community messages, chart, news and other stock related information. Share your ideas and get valuable insights from the community of like minded traders and investorsOct 31, 2023 · WALTHAM, Mass., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for ... Repligen Corp stock has a Growth Score of 82, Estimate Revisions Score of 39 and Quality Score of 71. Comparing Steris PLC and Repligen Corp’s grades, scores and metrics can act as a solid basis to determine whether they may be a good investment or not. You’ll also want to look at your portfolio’s asset allocation as well as your risk ...Get real-time Repligen (RGEN) stock price quotes, analyst insights, forecasts, news, and information you need to help your stock trading and investing.First quarter 2021 adjusted EPS increased to $0.68 per fully diluted share, compared to $0.32 in the 2020 period, an increase of $0.37, or 116%. Cash and cash equivalents, which are GAAP metrics ...Dimensional Fund Advisors LP raised its position in Repligen Co. (NASDAQ:RGEN – Free Report) by 8.2% during the 2nd quarter, HoldingsChannel.com …Repligen Corp’s stock is NA in 2023, NA in the previous five trading days and down 22.3% in the past year. Currently, Repligen Corp’s price-earnings ratio is 64.0. Repligen Corp’s trailing 12-month revenue is $729.3 million with a 18.9% net profit margin. Year-over-year quarterly sales growth most recently was -23.3%.Repligen Corporation Stock price Equities RGEN US7599161095 Medical Equipment, Supplies & Distribution Summary Quotes Charts News Ratings Calendar …

Get the latest Repligen Corporation (RGEN) stock news and headlines to help you in your trading and investing decisions. ... Raising target price to $161.00REPLIGEN CORP has an ... Nov. 14, 2023 ...Repligen Corp. historical stock charts and prices, analyst ratings, financials, and today’s real-time RGEN stock price. Repligen Corp. historical stock charts and prices, analyst ratings, financials, and today’s real-time RGEN stock price.You may have a lot of questions if you are interested in investing in the stock market for the first time. One question that beginning investors often ask is whether they need a broker to begin trading.Instagram:https://instagram. home loan programs for nursesjnj kenvuedairyland motorcycle insurance reviewsishares msci japan etf The stock of Repligen Corp. (NASDAQ: RGEN) has increased by 2.04 when compared to last closing price of 157.00. Despite this, the company has experienced a 2.74% gain in its stock price over the last five trading sessions. GlobeNewsWire reported 2023-11-07 that WALTHAM, Mass., Nov. 07, 2023 (GLOBE NEWSWIRE) — Repligen …Nov 30, 2023 · Repligen Corp’s stock is NA in 2023, NA in the previous five trading days and down 7.08% in the past year. Currently, Repligen Corp’s price-earnings ratio is 78.5. Repligen Corp’s trailing 12-month revenue is $669.8 million with a 17.3% net profit margin. Year-over-year quarterly sales growth most recently was -29.6%. cenn stock price prediction 2023qqq vs spy Invest in Repligen Corp on Stash Repligen Corporation is a bioprocessing company. The Company is focused on the development, manufacture and commercialization of products used to improve the interconnected phases of the biological drug manufacturing process.Third quarter 2023 adjusted gross profit was $59.3 million, a 48% decrease year-over-year and nearly $60 million of lower revenue, and on a lower adjusted gross margin, which was 42% in the third ... chargepoint stock forecast Get instant access to exclusive stock lists, expert market analysis and powerful tools with 2 months of IBD Digital for only $20! Get market updates, educational videos, webinars, and stock analysis. Learn how you can make more money with IBD's investing tools, top-performing stock lists, and educational content.Repligen Corp’s stock is NA in 2023, NA in the previous five trading days and down 24.63% in the past year. Currently, Repligen Corp’s price-earnings ratio is 60.3. Repligen Corp’s trailing 12-month revenue is $729.3 million with a 18.9% net profit margin. Year-over-year quarterly sales growth most recently was -23.3%.